News

News 07.02.2019 Zurich-Schlieren, Switzerland, February 7, 2019. Molecular Partners AG (SIX: MOLN), a clinical-stage biotech company pioneering the use of DARPin® therapeutics to treat serious diseases, today announced its unaudited financial results for 2018 and corporate highlights for the fourth quarter 2018. The fourth quarter was marked by positive phase 3 efficacy data presented for...

News 19.12.2018 Parties Will Jointly Develop MP0310, a Pre-clinical FAP x 4-1BB Multi-Specific DARPin® Molecule, in Combination with Amgen’s Oncology Assets, Including BiTE® Molecules Molecular Partners Retains Rights to Develop MP0310 in Combination With its Pipeline Products ZURICH-SCHLIEREN, SWITZERLAND and THOUSAND OAKS, Calif.– (Dec. 19, 2018) – Molecular Partners AG (SIX: MOLN), a clinical-stage...

News 17.12.2018 Schlieren (Zurich), Switzerland, December 17, 2018 – Kuros Biosciences (SIX: KURN) has completed a transformational year, having realized first sales of its MagnetOs bone graft substitute in the U.S. and Europe and raised capital to support the roll-out of MagnetOs, and fund the Phase II clinical trial of fibrinPTH (KUR-113) in spinal...

News 10.12.2018 Schlieren (Zurich), Switzerland, December 10, 2018 – Kuros Biosciences (SIX: KURN) today announced that it has received 510(k) clearance from the US Food and Drug Administration (FDA) for extending MagnetOs Putty indications to use as a stand-alone bone graft in extremities and pelvis. This is in addition to the existing...

News 06.12.2018 Zurich-Schlieren, Switzerland, and New York, December 6, 2018. Molecular Partners AG (SIX: MOLN), a clinical-stage biopharmaceutical company pioneering the use of DARPin® therapeutics* to treat serious diseases, today announces the continued progress of its pipeline of proprietary therapeutic product candidates in oncology and immuno-oncology, as well as in ophthalmology together...